| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K19103580 | CTRPv2 | pan-cancer | AAC | 0.076 | 0.1 |
| mRNA | CR-1-31B | CTRPv2 | pan-cancer | AAC | 0.065 | 0.1 |
| mRNA | ETP-46464 | CTRPv2 | pan-cancer | AAC | 0.081 | 0.1 |
| mRNA | STF-31 | CTRPv2 | pan-cancer | AAC | 0.071 | 0.1 |
| mRNA | BRD-K96431673 | CTRPv2 | pan-cancer | AAC | -0.18 | 0.1 |
| mRNA | IU1 | CTRPv2 | pan-cancer | AAC | 0.076 | 0.1 |
| mRNA | Irinotecan | gCSI | pan-cancer | AAC | 0.088 | 0.1 |
| mRNA | AZ-3146 | CTRPv2 | pan-cancer | AAC | 0.069 | 0.1 |
| mRNA | lenalidomide | GDSC1000 | pan-cancer | AAC | 0.067 | 0.1 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.067 | 0.1 |